Trinity Biotech (TRIB) Operating Leases (2019 - 2025)
Trinity Biotech's Operating Leases history spans 7 years, with the latest figure at $10.6 million for Q2 2025.
- On a quarterly basis, Operating Leases rose 3.48% to $10.6 million in Q2 2025 year-over-year; TTM through Jun 2025 was $10.6 million, a 3.48% increase, with the full-year FY2024 number at $10.5 million, down 3.63% from a year prior.
- Operating Leases hit $10.6 million in Q2 2025 for Trinity Biotech, up from $10.5 million in the prior quarter.
- Over the last five years, Operating Leases for TRIB hit a ceiling of $13.9 million in Q4 2021 and a floor of $9.7 million in Q3 2024.
- Historically, Operating Leases has averaged $11.3 million across 5 years, with a median of $10.9 million in 2023.
- Biggest five-year swings in Operating Leases: dropped 16.42% in 2021 and later increased 3.48% in 2025.
- Tracing TRIB's Operating Leases over 5 years: stood at $13.9 million in 2021, then fell by 11.53% to $12.3 million in 2022, then fell by 11.37% to $10.9 million in 2023, then dropped by 3.63% to $10.5 million in 2024, then grew by 0.73% to $10.6 million in 2025.
- Business Quant data shows Operating Leases for TRIB at $10.6 million in Q2 2025, $10.5 million in Q4 2024, and $9.7 million in Q3 2024.